Licensing arrangements - Zentalis Pharmaceuticals (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Jan. 05, 2024 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Issuance of common stock | $ 221 | ||
License agreement with Zentalis Pharmaceuticals, Inc | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
License Agreement, Upfront Payment in Cash | $ 15,000 | ||
Stock issued | 2,298,586 | ||
Issuance of common stock | $ 23,400 | $ 23,388 | |
Share Price | $ 11.12 | ||
Percentage of discount related to unregistered share restrictions to be deducted from the share price | 8.50% | ||
Transaction cost | $ 200 | ||
Maximum amount payable | 150,000 | ||
Additional amount payable | $ 25,000 |
X | ||||||||||
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in an asset acquisition. No definition available.
|
X | ||||||||||
- Definition The amount of maximum additional aggregate payment payable under the license agreement. No definition available.
|
X | ||||||||||
- Definition The amount of maximum aggregate payment payable under the license agreement. No definition available.
|
X | ||||||||||
- Definition Amount of transaction costs incurred in transactions under the license agreement. No definition available.
|
X | ||||||||||
- Definition Represents the upfront payment in cash under license agreement. No definition available.
|
X | ||||||||||
- Definition Represents the discount percentage related to unregistered share restrictions. No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|